Drug Trial Radar · NCT06830798
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
May 19, 2025
Primary completion
Nov 30, 2027
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Conditions
- Delayed Graft Function
- DGF
- Kidney Transplant
Interventions
RavulizumabDrug
Participants will receive ravulizumab via intravenous (IV) infusion.
PlaceboDrug
Participants will receive placebo via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Freedom from DialysisTime frame: Through 90 days post-transplant
Locations
130 sites in 18 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Francisco, California · Withdrawn
Research Site
San Francisco, California · Recruiting
Research Site
Stanford, California · Recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Fairway, Kansas · Recruiting
Research Site
Lexington, Kentucky · Recruiting
Research Site
Kenner, Louisiana · Recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
Livingston, New Jersey · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Durham, North Carolina · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Greenville, South Carolina · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Charlottesville, Virginia · Recruiting
Research Site
Richmond, Virginia · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Milwaukee, Wisconsin · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
Capital Federal, Argentina · Not yet recruiting
Research Site
Córdoba, Argentina · Recruiting
Research Site
Adelaide, Australia · Recruiting
Research Site
Brisbane, Australia · Recruiting
Research Site
Camperdown, Australia · Recruiting
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.